Market Research Report on Drug Coated Balloons for Coronary Artery Disease in 2025
In 2025, the global market for drug-coated balloons (DCBs) for coronary artery disease (CAD) continues to represent one of the most dynamic and rapidly evolving segments within the broader interventional cardiology landscape. The growing prevalence of CAD is a major health concern worldwide, given its status as the leading cause of morbidity and mortality in both developed and developing countries. As per the World Health Organization, CAD is responsible for an estimated 17.9 million deaths annually, underscoring the urgent need for innovative technologies and treatment strategies. In this context, drug-coated balloons have emerged as a pivotal advancement, offering a unique therapeutic approach that combines mechanical dilatation with localized drug delivery, thereby addressing several limitations associated with traditional treatments such as bare-metal stents (BMS) and drug-eluting stents (DES).
The adoption of DCB technology is influenced by several key market drivers. Foremost among these is the continued focus on reducing restenosis rates and late thrombotic events that have been correlated with conventional stent-based therapies. Drug-coated balloons, typically coated with antiproliferative agents such as paclitaxel or sirolimus, facilitate inhibition of neointimal hyperplasia without leaving behind a permanent metallic scaffold. This approach is of particular importance in small vessel disease and in-stent restenosis (ISR), settings where repeated implantation of metal devices can pose significant complications. The growing body of clinical evidence supporting the effectiveness of DCBs in these scenarios is expanding their indication base beyond their initial adoption.
In line with global trends towards personalized and minimally invasive therapy, DCBs have appealed to both clinicians and patients for their safety profile and versatility. As Dr. Anna Goldberg, Director of Cardiovascular Research at the European Heart Institute, notes, “DCBs fit an increasingly prominent clinical need for ‘leave nothing behind’ strategies in PCI, aiming to minimize foreign-body exposure and optimize vessel healing.” She further highlights the adaptability of DCBs for complex lesion subsets—such as bifurcations, long lesions, and small-caliber vessels—where traditional stents may not yield optimal results.
Market trends in 2025 indicate robust growth potentials for DCBs, supported by ongoing innovation and expanding clinical application. According to a 2025 report by MarketsandMarkets, the global drug-coated balloon market for coronary applications is expected to surpass USD 1.6 billion by 2028, registering a compound annual growth rate (CAGR) of 14%. This remarkable rise is underpinned by escalating CAD burdens, increased penetration in emerging healthcare markets, and the push for next-generation, sirolimus-eluting DCB technologies. Geographically, the Asia-Pacific region, in particular, is projected to outpace growth in North America and Europe, driven by large patient pools, improving access to advanced therapies, and the gradual reimbursement expansion for novel endovascular products.
The evolution of DCB technology itself further underscores key industry trends. Whereas early DCBs relied predominantly on paclitaxel due to its rapid absorption and durable antiproliferative effects, concerns surrounding paclitaxel toxicity and late mortality risks reported in peripheral arterial disease (PAD) studies led to increased scrutiny from global regulatory bodies. This prompted a new wave of development: several clinical trials are ongoing to assess the safety and efficacy of sirolimus-based coatings, which may offer a superior safety profile and extended bioactivity compared to paclitaxel. For instance, the prospective, multicenter SIRONA trial—concluded in late 2024—reported non-inferior efficacy for sirolimus DCBs versus paclitaxel DCBs in the treatment of ISR, without significant safety concerns.
Commenting on this shift, Professor Michel Renard, Chief Interventional Cardiologist at the Paris Cardiology Center, stated, “The promise of sirolimus DCBs aligns with clinicians’ search for both efficacy and safety, especially as regulatory agencies and payers demand more comprehensive long-term data. Having multiple drug options enhances our ability to tailor therapy to individual patient needs and risk profiles.” Renard’s remarks speak to a broader trend of diversification within the DCB product landscape, with leading manufacturers investing heavily in proprietary coatings, new excipient formulations, and optimized balloon catheter platforms to differentiate their offerings.
Innovation is further catalyzed by advances in balloon delivery platforms. Device manufacturers are focusing on improved drug transfer efficiency, lower coating loss during transit, and enhanced deliverability in tortuous anatomy. Noteworthy developments include semi-compliant and super-compliant balloon designs, coatings with nano-carrier delivery, and integration of imaging modalities for precise lesion assessment. As these technologies mature, they are likely to expand operator confidence and facilitate DCB adoption in more varied and complex clinical scenarios.
From a reimbursement and regulatory perspective, the DCB market has navigated a complex environment. Early challenges hampered adoption, particularly in the United States, where lack of robust payment models for DCB therapy in de novo coronary lesions limited uptake to investigational or specialized cases. However, throughout 2023 and 2024, progress in clinical guideline inclusion (such as ESC and ACC/AHA recommendations), FDA approvals, and expanded reimbursement frameworks have markedly improved access to DCBs for coronary applications. In 2023, CMS finalized coverage for DCBs in select coronary ISR cases, a move widely viewed as a catalyst for broader acceptance and utilization within hospital systems and catheterization labs.
The competitive landscape is marked by participation from both established medtech giants—such as Medtronic, Boston Scientific, and B. Braun—as well as emerging innovators and regional challengers. These organizations are now aiming to combine strong clinical data with health economic evidence, demonstrating not only improved patient outcomes but also cost efficiencies over the stent-centric paradigm. As Dr. Simon Lee, healthcare economist at the London School of Hygiene & Tropical Medicine, has observed, “The shift towards DCBs reflects not just a therapeutic evolution, but a potential solution for cost containment within cardiology—minimizing re-intervention rates and hospital stays, which are key drivers of expenditure in CAD care.” This economic appeal is particularly relevant for single-payer systems and developing countries with constrained healthcare budgets.
Patient-centricity and shared decision-making are increasingly integral to DCB market growth. Many patients, particularly those at increased risk for bleeding or with previous stent complications, express preferences for non-permanent solutions. DCBs’ compatibility with abbreviated dual antiplatelet therapy (DAPT) regimens is being explored, an area of great interest as the overall drive towards personalized medicine intensifies. A 2024 meta-analysis published in the Journal of Interventional Cardiology concluded that DCB-based strategies could enable shorter DAPT durations (as little as 1-3 months in select cases), without compromising long-term outcomes—a decisive advantage for elderly or polymedicated patients.
Despite these positive developments, several challenges temper the pace of DCB market expansion. Variability in operator technique, the lack of standardized protocols, and incomplete understanding of lesion preparation all impact outcomes in real-world practice. The procedural success of DCB therapy is highly dependent on meticulous vessel preparation, including adequate pre-dilatation and optimal lesion modification. To address these gaps, leading cardiovascular societies are producing standardized guidelines and industry partners are offering robust physician training and education programs. Digital health solutions, including artificial intelligence-driven case planning and virtual reality simulation for interventional training, are beginning to play a role in overcoming operator learning curves as well.
The role of real-world evidence (RWE) and long-term outcome registries is set to become more prominent in supporting DCB integration. Randomized controlled trials (RCTs) remain the gold standard but are often limited in sample size and external validity. The 2024 release of the DCB Global Registry, encompassing over 12,000 patient cases across North America, Europe, and Asia, has provided invaluable insights into effectiveness, safety, procedural nuances, and patient selection. Data from such registries are increasingly influencing reimbursement and clinical policy decisions, especially as health technology assessment (HTA) bodies in Europe and Asia demand real-world cost-effectiveness evidence for new medical technologies.
Another emerging trend is the combination of DCBs with intravascular imaging such as optical coherence tomography (OCT) and intravascular ultrasound (IVUS). These imaging modalities facilitate precise lesion characterization, aiding in the identification of ideal DCB candidates and optimizing both lesion preparation and balloon sizing. Early research indicates that integration of imaging-guided PCI with DCB use significantly enhances post-procedural vessel patency and reduces adverse events. As imaging technology becomes more accessible and its utility more widely appreciated, these hybrid strategies are anticipated to become a cornerstone of contemporary CAD intervention practice.
Looking at the future pipeline, late-stage clinical trials are exploring DCB applications in de novo large vessel disease, acute myocardial infarction, and multivessel coronary disease. Recent, high-profile studies such as the DEBUT II and PICASSO III trials are anticipated to report results in late 2025 and early 2026, respectively. These studies could redefine guideline recommendations and propel further expansion of DCB indications. The focus on pediatric and rare coronary syndromes is similarly mounting, as device companies invest in smaller-diameter and specialized balloon designs for these underserved populations.
Regional adoption patterns reflect underlying differences in healthcare systems, population needs, and regulatory frameworks. Europe remains the largest market for coronary DCBs in 2025, a position supported by early regulatory approval, widespread physician acceptance, and integration into clinical practice guidelines. The Asia-Pacific region, led by China, India, and Japan, is rapidly closing the gap, driven by increased CAD incidence, infrastructure expansion, and stronger local manufacturing presence. North America, meanwhile, is seeing accelerated growth following recent regulatory and reimbursement advances, though clinicians remain vigilant regarding best practices and long-term outcomes.
To further capitalize on regional and global market opportunities, leading DCB manufacturers are pursuing both organic growth and partnership strategies. Mergers and acquisitions, codevelopment agreements with drug formulation specialists, and academic collaborations for clinical research are all on the rise. In 2024, several notable partnerships—such as the collaboration between Medtronic and a leading Asian biotech firm—have aimed to leverage regional strengths in biopharmaceutical innovation and local market access to speed up the entry of next-generation DCBs.
Sustainability and environmental concerns, while less prominent in cardiology than in other device spaces, are beginning to feature in procurement and hospital value analysis discussions. The reduced implantation of permanent devices with DCBs supports overall efforts to lower the environmental footprint of interventional procedures. Manufacturers are responding with recyclable packaging, environmentally optimized balloon materials, and streamlined supply chain practices—all of which are likely to become more important in public tenders and institutional purchasing decisions over the coming years.
Finally, the interplay between regulatory innovation and clinical practice adaptation remains critical. As the scientific understanding of DCBs deepens, regulatory pathways are adjusting to facilitate earlier market entry for high-performing, well-supported products. Adaptive trial designs, conditional approval mechanisms contingent on RWE, and expedited pathways for breakthrough devices are increasingly utilized by agencies such as the FDA, EMA, NMPA, and PMDA. This regulatory flexibility, combined with robust post-marketing surveillance commitments, helps ensure patient safety while enabling faster access to promising therapies.
Industry experts unanimously agree that the continued rise of DCBs is not a mere fad but a sustained paradigm shift in the management of CAD. “DCBs will not fully replace drug-eluting stents, but they will transform the interventional toolbox, providing professionals with the flexibility to match the best device to each unique clinical setting and patient biology,” summarizes Dr. Felix Watanabe, chairman of the 2024 World Congress of Interventional Cardiology. As technical refinements, clinical data, and physician expertise coalesce, the global market for drug-coated balloons in coronary interventions is primed for continued expansion, innovation, and impact through 2025 and beyond.
https://pmarketresearch.com/hc/drug-coated-balloon-for-coronary-artery-disease-market/
Comments
Post a Comment